| Nome |
# |
|
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations, file e291c0d9-d4d5-cddb-e053-3a05fe0aa144
|
104
|
|
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy, file e291c0d9-ba99-cddb-e053-3a05fe0aa144
|
86
|
|
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study., file e291c0d7-180d-cddb-e053-3a05fe0aa144
|
66
|
|
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?, file e291c0d9-026f-cddb-e053-3a05fe0aa144
|
62
|
|
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study, file e291c0d9-7daa-cddb-e053-3a05fe0aa144
|
52
|
|
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study, file e291c0d8-938a-cddb-e053-3a05fe0aa144
|
50
|
|
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents, file e291c0d9-d6b8-cddb-e053-3a05fe0aa144
|
50
|
|
Quality of life and psychological impact in patients with atopic dermatitis, file e291c0d9-bddd-cddb-e053-3a05fe0aa144
|
35
|
|
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study., file e291c0d9-1ef6-cddb-e053-3a05fe0aa144
|
19
|
|
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab, file e291c0d8-bc57-cddb-e053-3a05fe0aa144
|
16
|
|
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study, file 03272474-2f6b-43c6-9ca7-102e32fb8240
|
11
|
|
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients, file c8b7d3f2-6f7e-478a-8386-b817947e4d82
|
7
|
|
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients., file e291c0d6-bf7c-cddb-e053-3a05fe0aa144
|
4
|
|
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement, file ea1845b4-3eb9-4d22-b006-c7945ea6fca3
|
4
|
|
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series, file 75cb8f3d-e56d-4bc0-b34c-b42396a8d5df
|
3
|
|
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study, file 9eb83a69-e29b-4fe5-8e37-c70598b4085c
|
3
|
|
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy, file e291c0d7-7ca2-cddb-e053-3a05fe0aa144
|
3
|
|
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up, file e291c0d8-bc54-cddb-e053-3a05fe0aa144
|
3
|
|
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks, file 4c2c9724-6449-42ab-bded-ad051e90e6b5
|
2
|
|
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis, file d3fd15eb-a386-483e-80cc-6ca3f7d7a272
|
2
|
|
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients., file e291c0d6-b1f0-cddb-e053-3a05fe0aa144
|
2
|
|
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies, file e291c0d6-d43e-cddb-e053-3a05fe0aa144
|
2
|
|
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center,
retrospective, real-life study up to 52 weeks observation, file e291c0d7-11d8-cddb-e053-3a05fe0aa144
|
2
|
|
Skin immunity and its dysregulation in psoriasis, file e291c0d7-d665-cddb-e053-3a05fe0aa144
|
2
|
|
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study, file e291c0d7-f491-cddb-e053-3a05fe0aa144
|
2
|
|
Pharmacotherapeutic management of psoriasis in adolescents and children, file e291c0d8-1341-cddb-e053-3a05fe0aa144
|
2
|
|
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis, file e291c0d8-ba82-cddb-e053-3a05fe0aa144
|
2
|
|
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab, file e291c0d8-d400-cddb-e053-3a05fe0aa144
|
2
|
|
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study., file e291c0d8-eb64-cddb-e053-3a05fe0aa144
|
2
|
|
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience, file e291c0d8-ef04-cddb-e053-3a05fe0aa144
|
2
|
|
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies, file e291c0d8-f27b-cddb-e053-3a05fe0aa144
|
2
|
|
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study), file 5fe79d28-1f80-49fc-93bb-57fc5528c572
|
1
|
|
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab”, file 9216f2f0-213b-4975-8050-910db6bc1544
|
1
|
|
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy, file c84625a9-a789-49ac-aaa0-3464efa3321b
|
1
|
|
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice, file e291c0d5-4696-cddb-e053-3a05fe0aa144
|
1
|
|
Tildrakizumab for treating psoriasis, file e291c0d6-ad19-cddb-e053-3a05fe0aa144
|
1
|
|
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the
Literature, file e291c0d6-b226-cddb-e053-3a05fe0aa144
|
1
|
|
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance
analysis in Caucasian psoriatic patients, file e291c0d6-da20-cddb-e053-3a05fe0aa144
|
1
|
|
Photo-recall cutaneous reaction to gemcitabine, file e291c0d6-dbbd-cddb-e053-3a05fe0aa144
|
1
|
|
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy, file e291c0d7-15ee-cddb-e053-3a05fe0aa144
|
1
|
|
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab, file e291c0d7-2000-cddb-e053-3a05fe0aa144
|
1
|
|
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial, file e291c0d7-3538-cddb-e053-3a05fe0aa144
|
1
|
|
Successful treatment of psoriatic crumbly nails with ustekinumab, file e291c0d7-791b-cddb-e053-3a05fe0aa144
|
1
|
|
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date, file e291c0d7-84c9-cddb-e053-3a05fe0aa144
|
1
|
|
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab, file e291c0d7-b9e8-cddb-e053-3a05fe0aa144
|
1
|
|
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab, file e291c0d7-d65f-cddb-e053-3a05fe0aa144
|
1
|
|
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature, file e291c0d7-d661-cddb-e053-3a05fe0aa144
|
1
|
|
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris, file e291c0d8-9787-cddb-e053-3a05fe0aa144
|
1
|
|
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts, file e291c0d8-9793-cddb-e053-3a05fe0aa144
|
1
|
|
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy, file e291c0d8-b59b-cddb-e053-3a05fe0aa144
|
1
|
|
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo, file e291c0d8-ba7c-cddb-e053-3a05fe0aa144
|
1
|
|
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study, file e291c0d8-bc46-cddb-e053-3a05fe0aa144
|
1
|
|
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases, file e291c0d8-bc50-cddb-e053-3a05fe0aa144
|
1
|
|
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis, file e291c0d8-bc52-cddb-e053-3a05fe0aa144
|
1
|
|
Linear psoriasis following the typical distribution of the sciatic nerve, file e291c0d8-bc58-cddb-e053-3a05fe0aa144
|
1
|
|
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis, file e291c0d8-cf07-cddb-e053-3a05fe0aa144
|
1
|
|
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature, file e291c0d8-d377-cddb-e053-3a05fe0aa144
|
1
|
|
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study, file e291c0d8-d385-cddb-e053-3a05fe0aa144
|
1
|
|
Italian guidelines in diagnosis and treatment of alopecia areata, file e291c0d8-e157-cddb-e053-3a05fe0aa144
|
1
|
|
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome, file e291c0d8-eb66-cddb-e053-3a05fe0aa144
|
1
|
|
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis, file e291c0d8-eb6a-cddb-e053-3a05fe0aa144
|
1
|
|
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab, file e291c0d8-eec4-cddb-e053-3a05fe0aa144
|
1
|
|
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis, file e291c0d8-eec9-cddb-e053-3a05fe0aa144
|
1
|
|
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks, file f9e8a879-691e-4d77-b859-6bb4e7babe4b
|
1
|
| Totale |
637 |